{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:05:51Z","timestamp":1790395551152,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti-IL17A therapies have proven effective for numerous inflammatory diseases including psoriasis, axial spondylitis and psoriatic arthritis. Modulating and\/or antagonizing protein\u2013protein interactions of IL17A cytokine binding to its cell surface receptors with oral therapies offers the promise to bring forward biologics-like efficacy in a pill to patients. We used an NMR-based fragment screen of recombinant IL17A to uncover starting points for small molecule IL17A antagonist discovery. By examining chemical shift perturbations in 2D [<jats:sup>1<\/jats:sup>H,<jats:sup>13<\/jats:sup>C-HSQC] spectra of isotopically labeled IL17A, we discovered fragments binding the cytokine at a previously undescribed site near the IL17A C-terminal region, albeit with weak affinity (&gt;\u2009250\u00a0\u00b5M). Importantly this binding location was distinct from previously known chemical matter modulating cytokine responses. Subsequently through analog screening, we identified related compounds that bound symmetrically in this novel site with two copies. From this observation we employed a linking strategy via structure-based drug design and obtained compounds with increased binding affinity (&lt;\u200950\u00a0nM) and showed functional inhibition of IL17A-induced cellular signaling (IC<jats:sub>50<\/jats:sub>~1\u00a0\u00b5M). We also describe a fluorescence-based probe molecule suitable to discern\/screen for additional molecules binding in this C-terminal site.<\/jats:p>","DOI":"10.1038\/s41598-022-18760-1","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:03:17Z","timestamp":1661508197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site"],"prefix":"10.1038","volume":"12","author":[{"given":"Eric R.","family":"Goedken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Argiriadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Petros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navasona","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay C.","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre M.","family":"Bodelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Goguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Slivka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Srikumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup K.","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bainan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell A.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha M.","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent S.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"18760_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy, M. J., Cua, D. J. & Gaffen, S. L. The IL-17 family of cytokines in health and disease. Immunity 50, 892\u2013906. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.021 (2019).","journal-title":"Immunity"},{"key":"18760_CR2","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","volume":"20","author":"X Li","year":"2019","unstructured":"Li, X., Bechara, R., Zhao, J., McGeachy, M. J. & Gaffen, S. L. IL-17 receptor-based signaling and implications for disease. Nat. Immunol. 20, 1594\u20131602. https:\/\/doi.org\/10.1038\/s41590-019-0514-y (2019).","journal-title":"Nat. Immunol."},{"key":"18760_CR3","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","volume":"155","author":"Z Yao","year":"1995","unstructured":"Yao, Z. et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 155, 5483\u20135486 (1995).","journal-title":"J Immunol"},{"key":"18760_CR4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3389\/fimmu.2019.01293","volume":"10","author":"S Swaidani","year":"2019","unstructured":"Swaidani, S., Liu, C., Zhao, J., Bulek, K. & Li, X. TRAF regulation of IL-17 cytokine signaling. Front. Immunol. 10, 1293. https:\/\/doi.org\/10.3389\/fimmu.2019.01293 (2019).","journal-title":"Front. Immunol."},{"key":"18760_CR5","doi-asserted-by":"publisher","first-page":"35603","DOI":"10.1074\/jbc.C600256200","volume":"281","author":"SH Chang","year":"2006","unstructured":"Chang, S. H., Park, H. & Dong, C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281, 35603\u201335607. https:\/\/doi.org\/10.1074\/jbc.C600256200 (2006).","journal-title":"J. Biol. Chem."},{"key":"18760_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ni1439","volume":"8","author":"Y Qian","year":"2007","unstructured":"Qian, Y. et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8, 247\u2013256. https:\/\/doi.org\/10.1038\/ni1439 (2007).","journal-title":"Nat. Immunol."},{"key":"18760_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","volume":"64","author":"C Gu","year":"2013","unstructured":"Gu, C., Wu, L. & Li, X. IL-17 family: Cytokines, receptors and signaling. Cytokine 64, 477\u2013485. https:\/\/doi.org\/10.1016\/j.cyto.2013.07.022 (2013).","journal-title":"Cytokine"},{"key":"18760_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 11, 415\u2013429. https:\/\/doi.org\/10.1038\/nrrheum.2015.53 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"18760_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya, N., Garg, A. V. & Gaffen, S. L. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 38, 310\u2013322. https:\/\/doi.org\/10.1016\/j.it.2017.01.006 (2017).","journal-title":"Trends Immunol."},{"key":"18760_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese, E. M. & Schett, G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat. Rev. Rheumatol. 14, 631\u2013640. https:\/\/doi.org\/10.1038\/s41584-018-0091-8 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"18760_CR11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191397","author":"I Prinz","year":"2020","unstructured":"Prinz, I., Sandrock, I. & Mrowietz, U. Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191397 (2020).","journal-title":"J. Exp. Med."},{"key":"18760_CR12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191123","author":"P Zwicky","year":"2020","unstructured":"Zwicky, P., Unger, S. & Becher, B. Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191123 (2020).","journal-title":"J. Exp. Med."},{"key":"18760_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","volume":"15","author":"K Ly","year":"2019","unstructured":"Ly, K. et al. Anti IL-17 in psoriasis. Expert Rev. Clin. Immunol. 15, 1185\u20131194. https:\/\/doi.org\/10.1080\/1744666X.2020.1679625 (2019).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"18760_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/14712598.2017.1363884","volume":"17","author":"A Balato","year":"2017","unstructured":"Balato, A. et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin. Biol. Ther. 17, 1363\u20131374. https:\/\/doi.org\/10.1080\/14712598.2017.1363884 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"18760_CR15","unstructured":"Michael Taylor, N. K. T., Connors, W. H., Shortsleeves, K. C., Seigal, B. J. Snedeker, C., Hale, S. P., Briggs, T. F., Favaloro, F. G., Cipriani, T. J., Yan, D., Alexander, S. L., Thorarensen, A. & Xing, L. Macrocyclic compounds for modulating IL-17. (2013)."},{"key":"18760_CR16","doi-asserted-by":"publisher","first-page":"30859","DOI":"10.1038\/srep30859","volume":"6","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. Sci. Rep. 6, 30859. https:\/\/doi.org\/10.1038\/srep30859 (2016).","journal-title":"Sci. Rep."},{"key":"18760_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-981-13-9367-9_5","volume":"1172","author":"S Liu","year":"2019","unstructured":"Liu, S. Structural Insights into the Interleukin-17 Family Cytokines and Their Receptors. Adv. Exp. Med. Biol. 1172, 97\u2013117. https:\/\/doi.org\/10.1007\/978-981-13-9367-9_5 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"18760_CR18","doi-asserted-by":"publisher","first-page":"26071","DOI":"10.1038\/srep26071","volume":"6","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide. Sci. Rep. 6, 26071. https:\/\/doi.org\/10.1038\/srep26071 (2016).","journal-title":"Sci. Rep."},{"key":"18760_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1359-6446(05)03386-6","volume":"10","author":"C Abad-Zapatero","year":"2005","unstructured":"Abad-Zapatero, C. & Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 10, 464\u2013469. https:\/\/doi.org\/10.1016\/S1359-6446(05)03386-6 (2005).","journal-title":"Drug Discov. Today"},{"key":"18760_CR20","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","volume":"274","author":"SB Shuker","year":"1996","unstructured":"Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531\u20131534. https:\/\/doi.org\/10.1126\/science.274.5292.1531 (1996).","journal-title":"Science"},{"key":"18760_CR21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/ncomms2880","volume":"4","author":"S Liu","year":"2013","unstructured":"Liu, S. et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat. Commun. 4, 1888. https:\/\/doi.org\/10.1038\/ncomms2880 (2013).","journal-title":"Nat. Commun."},{"key":"18760_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585\u2013600. https:\/\/doi.org\/10.1038\/nri3707 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"18760_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1517\/13543784.2013.806483","volume":"22","author":"A Chiricozzi","year":"2013","unstructured":"Chiricozzi, A. & Krueger, J. G. IL-17 targeted therapies for psoriasis. Expert Opin. Investig. Drugs 22, 993\u20131005. https:\/\/doi.org\/10.1517\/13543784.2013.806483 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"18760_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/09546634.2013.878448","volume":"26","author":"G Brown","year":"2015","unstructured":"Brown, G., Malakouti, M., Wang, E., Koo, J. Y. & Levin, E. Anti-IL-17 phase II data for psoriasis: A review. J. Dermatolog. Treat 26, 32\u201336. https:\/\/doi.org\/10.3109\/09546634.2013.878448 (2015).","journal-title":"J. Dermatolog. Treat"},{"key":"18760_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00422","author":"MD Andrews","year":"2022","unstructured":"Andrews, M. D. et al. Discovery of an oral, rule of 5 compliant, interleukin 17A protein-protein interaction modulator for the potential treatment of psoriasis and other inflammatory diseases. J. Med. Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00422 (2022).","journal-title":"J. Med. Chem."},{"key":"18760_CR26","unstructured":"BRACE, G. N. et al. Spirocyclic indolines as IL-17 modulators. (2018)."},{"key":"18760_CR27","unstructured":"Coates, D. A. et al. Imidazo[1,2-b]pyridazine il-17a inhibitors. (2020)."},{"key":"18760_CR28","unstructured":"Dack, K. N. et al. Amino-acid anilides as small molecule modulators of IL-17. (2020)."},{"key":"18760_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293\u2013302. https:\/\/doi.org\/10.1107\/S0907444911007773 (2011).","journal-title":"Acta Crystallogr. D"},{"key":"18760_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674. https:\/\/doi.org\/10.1107\/S0021889807021206 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"18760_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355\u2013367. https:\/\/doi.org\/10.1107\/S0907444911001314 (2011).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"18760_CR32","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1107\/S0907444904016427","volume":"60","author":"E Blanc","year":"2004","unstructured":"Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 60, 2210\u20132221. https:\/\/doi.org\/10.1107\/S0907444904016427 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"18760_CR33","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132. https:\/\/doi.org\/10.1107\/S0907444904019158 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"18760_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1107\/S0907444906016076","volume":"62","author":"S Wlodek","year":"2006","unstructured":"Wlodek, S., Skillman, A. G. & Nicholls, A. Automated ligand placement and refinement with a combined force field and shape potential. Acta Crystallogr. D 62, 741\u2013749. https:\/\/doi.org\/10.1107\/S0907444906016076 (2006).","journal-title":"Acta Crystallogr. D"},{"key":"18760_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877. https:\/\/doi.org\/10.1107\/S2059798319011471 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18760-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T01:37:42Z","timestamp":1676511462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18760-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18760"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18760-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ERG, MAA, PMB, PBC, JDD, SMG, NK, RAJ, SCP, AMP, WQ, PLR, PFS, MS, VSS, CS, AKU, AV, HW and HZ are employees of AbbVie. AMA, LG and BW were employees of AbbVie at the time of the study. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14561"}}